pdufa.bio
Home › Decisions › BMY 2026-06-01

BMY FDA decision — Jun 1, 2026

✓ APPROVED

Bristol-Myers Squibb Company — Camzyos (mavacamten) - (SCOUT-HCM) · Symptomatic obstructive hypertrophic cardiomyopath.

Run-up into the decision (T-120 → T+5)

PDUFA 6/1/26$62.37$50.6512/15/25
Daily close, T-120 (12/15/25) through T+5. Run-up high $62.37 on 3/3/26, low $50.65 on 12/17/25 (T-120 to T-1). FDA decision 6/1/26. Historical price action, not a forecast.

Key facts

FDA decision date2026-06-01
OutcomeApproved
Drug / candidateCamzyos (mavacamten) - (SCOUT-HCM)
CompanyBristol-Myers Squibb Company
120-day run-up (T-120→T-1)+9.6%
Not affiliated with or endorsed by the FDA. Informational and educational only — not investment advice. Verify against primary FDA / SEC / company filings. © 2026 pdufa.bio